ATE280235T1 - Plasmid zur herstellung von crm-protein und diphtherie-toxin - Google Patents

Plasmid zur herstellung von crm-protein und diphtherie-toxin

Info

Publication number
ATE280235T1
ATE280235T1 AT94101770T AT94101770T ATE280235T1 AT E280235 T1 ATE280235 T1 AT E280235T1 AT 94101770 T AT94101770 T AT 94101770T AT 94101770 T AT94101770 T AT 94101770T AT E280235 T1 ATE280235 T1 AT E280235T1
Authority
AT
Austria
Prior art keywords
plasmid
diphtheria toxin
crm197
protein
novel
Prior art date
Application number
AT94101770T
Other languages
English (en)
Inventor
Benjamin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE280235T1 publication Critical patent/ATE280235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94101770T 1993-03-05 1994-02-07 Plasmid zur herstellung von crm-protein und diphtherie-toxin ATE280235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2728393A 1993-03-05 1993-03-05

Publications (1)

Publication Number Publication Date
ATE280235T1 true ATE280235T1 (de) 2004-11-15

Family

ID=21836767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94101770T ATE280235T1 (de) 1993-03-05 1994-02-07 Plasmid zur herstellung von crm-protein und diphtherie-toxin

Country Status (21)

Country Link
US (1) US5614382A (de)
EP (1) EP0616034B1 (de)
JP (1) JP4144813B2 (de)
KR (1) KR100316004B1 (de)
CN (1) CN1100757A (de)
AT (1) ATE280235T1 (de)
AU (1) AU686126B2 (de)
BR (1) BR1100634A (de)
CA (1) CA2116914C (de)
CZ (1) CZ39394A3 (de)
DE (1) DE69434079T2 (de)
DK (1) DK0616034T3 (de)
ES (1) ES2231770T3 (de)
FI (1) FI112090B (de)
HU (1) HUT71320A (de)
IL (1) IL108822A (de)
NO (1) NO313758B1 (de)
NZ (1) NZ260027A (de)
PT (1) PT616034E (de)
SK (1) SK24094A3 (de)
ZA (1) ZA941548B (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638145D1 (de) * 1995-04-14 2010-04-22 Us Gov Health & Human Serv Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
WO1998039363A2 (en) 1997-03-05 1998-09-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
EP0968282A2 (de) * 1997-03-05 2000-01-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vektore und verfahren zur expression mutierter proteinen
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
CN1086945C (zh) * 1997-06-03 2002-07-03 胡章英 白喉口服液
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
KR101201120B1 (ko) 2003-12-17 2012-12-03 와이어쓰 엘엘씨 Ａβ 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
AR046960A1 (es) 2003-12-17 2006-01-04 Wyeth Corp Metodos para producir los conjugados portadores de peptidos inmunogenicos
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
ATE552839T1 (de) 2006-05-31 2012-04-15 Baroncini Luciana Pharmazeutische verwendung von immunologisch mit diphtherie-toxin korrelierten proteinmolekülen
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN101265288B (zh) * 2007-03-13 2012-03-21 齐鲁制药有限公司 Crm197突变体的纯化方法
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
EP3461496B1 (de) 2009-06-22 2023-08-23 Wyeth LLC Zusammensetzungen und verfahren zur herstellung von staphylococcus aureus serotyp-5 und 8-kapselpolysaccharid-konjugat-immunogenzusammensetzungen
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
US8530171B2 (en) 2010-03-30 2013-09-10 Pfenex Inc. High level expression of recombinant toxin proteins
AU2010201410B2 (en) * 2010-03-30 2015-04-30 Pelican Technology Holdings, Inc. High level expression of recombinant CRM197
ES2614807T3 (es) 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
KR101839496B1 (ko) * 2011-06-01 2018-03-19 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof
CN102766647A (zh) * 2012-07-25 2012-11-07 天津康希诺生物技术有限公司 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌
CA2881420C (en) 2012-08-16 2016-11-15 Pfizer Inc. Glycoconjugation processes and compositions
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
FI3363806T3 (fi) 2012-12-20 2023-01-31 Glykokonjugaatiomenetelmä
EP3792272A1 (de) 2013-01-04 2021-03-17 OBI Pharma, Inc. Impfstoffe mit erhöhter kohlenhydrat-antigen-dichte und einem neuartigen saponin-adjuvans
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104140972B (zh) * 2013-05-07 2018-01-23 上海惠盾生物技术有限公司 白喉毒素突变体crm197的制备方法
EP3511161A1 (de) 2013-08-26 2019-07-17 Corning Incorporated Laminierte struktur
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20160324949A1 (en) 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
NZ721943A (en) 2014-01-21 2022-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2710393C2 (ru) 2014-01-21 2019-12-26 Пфайзер Инк. Способ получения иммуногенного конъюгата капсульный полисахарид Streptococcus pneumoniae-белок-носитель
AU2015210674B2 (en) 2014-01-31 2017-08-24 Fina Biosolutions, Llc Expression and purification of CRM197 and related proteins
EP3443983B1 (de) 2014-02-14 2022-07-20 Pfizer Inc. Immunogene glykoproteinkonjugate
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2016079755A1 (en) 2014-11-20 2016-05-26 Biological E Limited Codon optimized polynucleotide for high level expression of crm197
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102045663B1 (ko) 2015-05-04 2019-11-15 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
EP3313436B1 (de) 2015-06-23 2020-12-23 Biological E Limited Multivalenter pneumokokken-konjugatimpfstoff
TWI756893B (zh) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
JP2019512233A (ja) 2016-03-10 2019-05-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
EP3474890A1 (de) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumokokken-polysaccharid-proteinkonjugat-zusammensetzung
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
JP7001686B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
EP3518965A1 (de) 2016-09-30 2019-08-07 Biological E Limited Mehrwertige pneumokokken-impfstoffzusammensetzungen mit polysaccharidproteinkonjugaten
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
AU2018208844B2 (en) 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
KR101908590B1 (ko) 2017-02-01 2018-10-16 (주)포바이오코리아 Crm197의 용해성 단백질 발현 및 정제 방법
CA3052621A1 (en) 2017-02-03 2018-08-09 Schadeck, Eva Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US20200054740A1 (en) 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
PT3612553T (pt) * 2017-04-22 2022-09-08 Biological E Ltd Método melhorado para a produção de alto nível de crm
HUE068482T2 (hu) 2017-09-07 2025-01-28 Merck Sharp & Dohme Llc Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR102812816B1 (ko) 2018-02-05 2025-05-27 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
KR102475419B1 (ko) * 2018-07-16 2022-12-07 주식회사 유바이오로직스 Crm197을 고농도로 발현하는 코리네박테리움 균주
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US12048739B2 (en) 2018-09-23 2024-07-30 Biological E Limited Purified capsular polysaccharides of Streptococcus pneumoniae
CN109100517A (zh) * 2018-10-08 2018-12-28 武汉生命科技股份有限公司 一种用于检测白喉抗体的抗原蛋白、试剂盒及制备方法
EP3893926A1 (de) 2018-12-12 2021-10-20 Pfizer Inc. Immunogene multiple hetero-antigen-polysaccharid-protein-konjugate und deren verwendung
BR112021011961A8 (pt) 2018-12-19 2023-02-07 Merck Sharp & Dohme Composições compreendendo conjugados de polissacarídeo-proteína de streptococcus pneumoniae e métodos de uso dos mesmos
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4107192A1 (de) 2020-02-21 2022-12-28 Pfizer Inc. Reinigung von sacchariden
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer Composições de escherichia coli e métodos das mesmas.
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
JP2023538736A (ja) 2020-08-26 2023-09-11 ファイザー・インク Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
EP4213870A1 (de) 2020-09-17 2023-07-26 Janssen Pharmaceuticals, Inc. Multivalente impfstoffzusammensetzungen und verwendungen davon
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR20220102871A (ko) 2021-01-14 2022-07-21 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346893A2 (de) 2021-05-28 2024-04-10 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
KR20230175284A (ko) 2021-05-28 2023-12-29 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
IL314243A (en) 2022-01-13 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN116942804A (zh) 2022-04-19 2023-10-27 上海瑞宙生物科技有限公司 多价肺炎球菌多糖结合疫苗的成分及其应用
CA3256617A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
TW202432182A (zh) 2022-10-24 2024-08-16 瑞士商愛杜西亞製藥有限公司 對抗克雷伯氏肺炎桿菌之疫苗
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (de) 2022-12-01 2025-10-08 Pfizer Inc. Pneumokokkenkonjugat-impfstoffformulierungen
KR20250120353A (ko) 2022-12-08 2025-08-08 이도르시아 파마슈티컬스 리미티드 클렙시엘라 뉴모니아에의 백신
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AR132702A1 (es) 2023-05-18 2025-07-23 Merck Sharp & Dohme Llc Compuestos y formulaciones adyuvantes útiles en vacunas neumocócicas
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
US20250161420A1 (en) 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
AR133640A1 (es) 2024-02-14 2025-10-22 Merck Sharp & Dohme Llc Vacunas neumocócicas conjugadas y métodos de uso de las mismas
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH660375A5 (it) * 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
FR2549855B1 (fr) * 1983-07-29 1987-03-27 Grp Genie Genetique Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues

Also Published As

Publication number Publication date
JP4144813B2 (ja) 2008-09-03
IL108822A0 (en) 1994-06-24
ZA941548B (en) 1994-10-03
DE69434079D1 (de) 2004-11-25
CZ39394A3 (en) 1995-02-15
EP0616034A3 (en) 1996-10-16
DE69434079T2 (de) 2005-02-24
FI112090B (fi) 2003-10-31
NO313758B1 (no) 2002-11-25
HU9400657D0 (en) 1994-05-30
AU5759594A (en) 1994-09-08
NO940774D0 (no) 1994-03-04
EP0616034A2 (de) 1994-09-21
SK24094A3 (en) 1995-03-08
CA2116914A1 (en) 1994-09-06
CA2116914C (en) 2005-02-08
AU686126B2 (en) 1998-02-05
US5614382A (en) 1997-03-25
FI941050L (fi) 1994-09-06
NZ260027A (en) 1996-03-26
JPH06292593A (ja) 1994-10-21
KR100316004B1 (ko) 2002-02-19
ES2231770T3 (es) 2005-05-16
PT616034E (pt) 2005-02-28
NO940774L (no) 1994-09-06
EP0616034B1 (de) 2004-10-20
KR940021731A (ko) 1994-10-19
FI941050A0 (fi) 1994-03-04
IL108822A (en) 2004-09-27
CN1100757A (zh) 1995-03-29
HUT71320A (en) 1995-11-28
DK0616034T3 (da) 2005-02-21
BR1100634A (pt) 1999-12-07

Similar Documents

Publication Publication Date Title
ATE280235T1 (de) Plasmid zur herstellung von crm-protein und diphtherie-toxin
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
DE88166T1 (de) Verfahren zum exprimieren eines gens.
IL103057A0 (en) Dna sequences encoding gelonin polypeptide
EP0769551A4 (de) Für die erhöhung der carotenoidensbeute nützliches dna-strang
DE69014046D1 (de) Verzweigungsenzym und dessen Verwendung.
DE68926893D1 (de) Verfahren zur Herstellung von clavulanic Säure
AU3475495A (en) Process for producing recombinant proteins, plasmids and modified cells
DE69224269D1 (de) Biosynthetisches Verfahren zur Herstellung von Protein
DE69535126D1 (de) Verfahren zur herstellung von sekundären metaboliten
DE59007117D1 (de) Optimierte Fermentationsverfahren zur Herstellung von Fremdproteinen in E.coli.
CA2121481A1 (en) Expression of polypeptides in e.coli under control of the e.coli mdh-gene promoter
RU94007083A (ru) Способ получения дифтерийного токсина или белка crm, плазмиды, микроорганизма
ATE190653T1 (de) Verfahren zur herstellung von rekombinanten und synthetischen peptiden und deren verwendung
DE69737007D1 (de) Protein-disulfidisomerase-Gen eines methylotrophen Hefestammes
KR970021294A (ko) 유기산 생성이 억제된 대장균 변이주

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0616034

Country of ref document: EP

REN Ceased due to non-payment of the annual fee